Find out what to get in the ground now for optimal success …read more
From:: DIY this old house
[video] Quicken Loans to HUD: You can’t have it both ways
In the latest update on its fight with the government, Quicken Loans CEO Bill Emerson commented on a recent quote from Housing and Urban Development Secretary Julian Castro. To Quicken Loans, HUD can’t ask for more people to lend as it decides to go after lenders for lending in the first place. Make sense? …read more
From:: Real Estate Wire
Mason-McDuffie Mortgage announces partnership with tech company Blend
Blend, winner of HousingWire’s Tech 100 award, teamed up with Mason-McDuffie to create a digital lending platform. The company wants to offer a more modern, digital experience to homebuyers. …read more
From:: Real Estate Wire
Hertz shares slide after wider-than-expected loss
Hertz Global Holdings Inc. shares declined in the extended session Monday after the car-rental company’s first-quarter results fell below Wall Street expectations. Hertz shares declined 3% to $8.50 after hours. The company reported an adjusted first-quarter loss of 12 cents a share on revenue of $2.31 billion. Analysts surveyed by FactSet had forecast a loss of 1 cent a share on revenue of $2.38 billion. For the year, Hertz sees adjusted earnings of 95 cents to $1.10 a share. Analysts expect 96 cents a share.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
Stamps.com soars 17% as its earnings crush expectations
Stamps.com Inc. shares surged in Monday’s extended session after the Internet-based postage service turned in better-than-expected quarterly results. Stamps.com reported it swung to a first-quarter profit of $13.2 million, or 71 cents a share, from a loss of $970,000, or 6 cents a share, a year earlier. On an adjusted basis, the company would have earned $1.72. Revenue grew 86% to $81.6 million. Analysts surveyed by FactSet had forecast earnings of 25 cents a share on revenue of $761 million. Stamps.com also raised its 2016 revenue outlook to $310 million to $330 million from $290 million to $310 million. It also hiked its adjusted EPS forecast to a range of $6.00 to $6.50 versus $5.00 to $5.50. Shares jumped 17% in after hours.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
Stamps.com soars 17% as its earnings crush expectations
Stamps.com Inc. shares surged in Monday’s extended session after the Internet-based postage service turned in better-than-expected quarterly results. Stamps.com reported it swung to a first-quarter profit of $13.2 million, or 71 cents a share, from a loss of $970,000, or 6 cents a share, a year earlier. On an adjusted basis, the company would have earned $1.72. Revenue grew 86% to $81.6 million. Analysts surveyed by FactSet had forecast earnings of 25 cents a share on revenue of $761 million. Stamps.com also raised its 2016 revenue outlook to $310 million to $330 million from $290 million to $310 million. It also hiked its adjusted EPS forecast to a range of $6.00 to $6.50 versus $5.00 to $5.50. Shares jumped 17% in after hours.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
Infoblox plummets after revenue warning
Infoblox Inc. warned investors Monday that revenue would come in well below expectations, and shares in the networking-software company dove more than 12% in late trading. Infoblox said it expects revenue for the first quarter to be $81 million to $82 million, after previously providing a forecast of $91 million to $93 million, and expects adjusted profit of 5 cents to 6 cents a share. Analysts polled by FactSet expected the company to report adjusted earnings of 6 cents a share on sales of $92 million. Infoblox also dropped its full-year revenue guidance to $354 million to $358 million, compared with a previous estimate of $370 to $380 million. Chief Executive Jesper Andersen, a former Cisco Systems Inc. executive who was brought in to stem a decline at Infoblox, said weakness in enterprise IT spending, especially in North America, was to blame for the shortfall. “We are actively addressing these near-term challenges by continuing to focus on improvements in sales execution and operational efficiency,” the CEO said in Monday’s announcement. Infoblox shares fell lower than $14 in late trading after closing with a 0.5% decline at $15.52. The company expects to fully report earnings and hold a conference call on May 25.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
NewLink shares plummet 40% after disappointing cancer drug study
NewLink Genetics Corp. shares plummeted in the extended session Monday after the biotech company said its study for a pancreatic cancer drug did not reach its primary goal. NewLink shares dropped 40% to $9.97 on heavy volume after hours following a brief trading halt. The company said a late-stage clinical trial for its algenpantucel-L treatment did not statistically improve survival rates in patients with resected pancreatic cancer. “In light of these negative results, our scientific and clinical teams will focus on other promising opportunities in our pipeline,” said Charles Link, NewLink chairman and chief executive, in a statement.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
NewLink shares plummet 40% after disappointing cancer drug study
NewLink Genetics Corp. shares plummeted in the extended session Monday after the biotech company said its study for a pancreatic cancer drug did not reach its primary goal. NewLink shares dropped 40% to $9.97 on heavy volume after hours following a brief trading halt. The company said a late-stage clinical trial for its algenpantucel-L treatment did not statistically improve survival rates in patients with resected pancreatic cancer. “In light of these negative results, our scientific and clinical teams will focus on other promising opportunities in our pipeline,” said Charles Link, NewLink chairman and chief executive, in a statement.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News
NewLink shares plummet 40% after disappointing cancer drug study
NewLink Genetics Corp. shares plummeted in the extended session Monday after the biotech company said its study for a pancreatic cancer drug did not reach its primary goal. NewLink shares dropped 40% to $9.97 on heavy volume after hours following a brief trading halt. The company said a late-stage clinical trial for its algenpantucel-L treatment did not statistically improve survival rates in patients with resected pancreatic cancer. “In light of these negative results, our scientific and clinical teams will focus on other promising opportunities in our pipeline,” said Charles Link, NewLink chairman and chief executive, in a statement.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News